William Chase - Jun 11, 2025 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
Director
Signature
Edward Dulac, attorney-in-fact
Stock symbol
NTLA
Transactions as of
Jun 11, 2025
Transactions value $
$0
Form type
4
Date filed
6/13/2025, 04:25 PM
Previous filing
May 30, 2025
Next filing
Jul 17, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
CHASE WILLIAM J Director C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE Edward Dulac, attorney-in-fact 2025-06-13 0001563572

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Award $0 +8K +29.97% $0.00 34.7K Jun 11, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Stock Option (right to buy) Award $0 +11.5K $0.00 11.5K Jun 11, 2025 Common Stock 11.5K $8.37 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2 This option was granted on June 11, 2025 with respect to 11,450 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

Remarks:

Exhibit 24.1 - Power of Attorney.